BRAF and malignant colon neoplasm: While the association between lineage and mutation proved a stronger predictor than lineage or mutation alone, in many cases the associations remained weak and in some cases such as BRAF and sensitivity to the MEK inhibitor in colon cancer have not been validated in clinical studies [23].